Table 1.

Characteristics of enrolled patients (n = 391)

Characteristics	n (%)
Females	259 (66.2)
Diagnosis:
• Rheumatoid arthritis	221 (56.5)
• Psoriatic arthritis	64 (16.4)
• Spondylarthritis	67 (17.1)
• Other diagnoses	39 (10.0)
Therapy:
• Glucocorticoids:
o  ≥ 7.5 mg/die prednisone equivalent	38 (9.7)
• csDMARD:
o Methotrexate	89 (22.8)
o Hydroxychloroquine	27 (6.9)
o Other	23 (5.9)
• bDMARD:
o Etanercept	83 (21.2)
o Adalimumab	86 (22.0)
o Golimumab	32 (8.2)
o Certolizumab	17 (4.3)
o Infliximab	10 (2.6)
o Tocilizumab	44 (11.2)
o Sarilumab	11 (2.8)
o Abatacept	48 (12.3)
o Anakinra	3 (0.8)
o Rituximab	7 (1.8)
o Secukinumab	19 (4.9)
• tsDMARDs:
o Tofacitinib	11 (2.8)
o Baricitinib	6 (1.5)
o Upadacitinib	1 (0.3)
o Apremilast	4 (1.0)

csDMARD conventional synthetic disease–modifying antirheumatic drugs, bDMARD biological disease-modifying antirheumatic drugs, tsDMARD targeted synthetic disease-modifying antirheumatic drugs